Finnish national focal point
The national focal point is hosted by the Finnish Institute for Health and Welfare (THL). The Finnish Institute for Health and Welfare (THL) is an independent state-owned expert and research institute that promotes the welfare, health and safety of the population.
News
Events, meetings and visits
- Coming soon: European Drug Report 2024 to be released on 11 June
- Celebrating European Day of Languages: EMCDDA multilingual drug glossary unveiled
- Reitox network meets to showcase 2022 highlights, new digital resources and plan future activities
- 25 years of early warning and response to new psychoactive substances in Europe
- Penalties for drug law offences in Europe ‘at a glance’ — new countries added to online tool
- EMCDDA launches 2021 European Web Survey on Drugs to assess patterns of drug use in over 30 countries
Events
Events, meetings and visits
- Launch event: European Drug Report 2024 (11.06.2024, Online)
- Expert meeting on drug-related infectious diseases (DRID) 2024 (07.11.2024 to 08.11.2024, EMCDDA, Lisbon)
- Treatment Demand Indicator (TDI) expert meeting 2024 (17.09.2024 to 18.09.2024, Lisboa, Portugal)
- 24th Annual meeting of the Reitox Early Warning System (EWS) Network (25.09.2024 to 26.09.2024, Lisbon, Portugal)
- Prevalence and patterns of drug use expert meeting 2024 (18.06.2024 to 19.06.2024, Online)
- 69th Reitox extended meeting (21.11.2023 to 23.11.2023, )
Publications
Publications related to this partner
The elimination barometer for hepatitis B and C among people who inject drugs is designed to support countries affiliated to the EMCDDA in monitoring their progress towards the Sustainable Development Goal 3.3 and the elimination of viral hepatitis as a major public health threat by 2030.
Heroin remains Europe’s most commonly used illicit opioid and is also the drug responsible for a large share of the health burden attributed to illicit drug consumption.
MDMA is a synthetic drug chemically related to the amphetamines, but with somewhat different effects. In Europe, MDMA use has generally been associated with episodic patterns of consumption in the context of nightlife and entertainment settings.
Amphetamine, methamphetamine and, more recently, synthetic cathinones are all synthetic central nervous system stimulants available on the drug market in Europe.
The market for new psychoactive substances is characterised by the large number of substances that have appeared in this area and that new compounds continue to be detected each year.
The European Drug Report 2023: Trends and Developments presents the EMCDDA’s latest analysis of the drug situation in Europe.
Document library
Relevant external documents or commissioned reports from the EMCDDA Document library
- Ways of using drugs and means of procurement in Finland: European online survey on drugs 2021 ( )
- Government of Finland (2021) Finland's Government Resolution on drug policy 2021–23 ( )
- Ministry of Social Affairs and Health, Finland (2021) Action Plan on Alcohol, Tobacco, Drugs and Gambling - Interim review and measures to be enhanced by 2025 ( )
- Ministry of Social Affairs and Health, Finland (2020) Municipal surveys on substance abuse prevention in 2020 and 2016 ( )
- Ministry of the Interior, Finland (2021) Government Report on Internal Security ( )
- Ministry of Social Affairs and Health, Finland (2021) Substance abuse and addiction strategy guidelines to 2030 ( )
Media library
Related photos, infographics and videos from our Media library
Contact information
Finnish Institute for Health and Welfare
Ms Sanna Rönkä
Helsinki
Finland